Rezolute announces completion of enrollment in the phase 3 sunrize study of ersodetug in patients with congenital hyperinsulinism

Target enrollment exceeded with 62 participants enrolled, including approximately 15 percent from u.s. sites topline data is anticipated in december of 2025 redwood city, calif., may 28, 2025 (globe newswire) -- rezolute, inc. (nasdaq: rzlt) (“rezolute” or the “company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (hi), today announced that enrollment is complete in the sunrize study, a global, phase 3 multicenter, double-blind, randomized, placebo-controlled, parallel arm study designed to evaluate the efficacy and safety of ersodetug for the treatment of hypoglycemia in patients with congenital hi.
RZLT Ratings Summary
RZLT Quant Ranking